August 3, 2025
A technical walkthrough of how I used LLMs strategically to improve name harmonization for clinical trial sponsors while minimizing non-determinism.
Competitive Intel from What Biotech Does, Not What It Says
RxDataLab surfaces operational signals like hiring spikes, trial activity, regulatory filings, and patent shifts that help investors and strategy teams understand what biotech companies may do next.
Recent Analysis
View allJune 30, 2025
Learn how to parse SEC Form D filings into a private capital database for biotech and venture research.
June 22, 2025
Eikon Therapeutics has raised over $1B and claims to have a revolutionary drug discovery platform, but its clinical pipeline remains dominated by acquired oncology assets. This report analyzes Eikon’s funding, trials, and patent strategy to assess whether its platform is delivering.
Biotech intelligence built for analysts and agile teams
RxDataLab examines biotechnology companies by analyzing clinical trials, regulatory filings, patents, and hiring patterns—especially in neuroscience and AI-driven drug discovery. Our research combines scientific domain expertise with systematic alternative data analysis to assess what’s real, what’s likely, and what investors should watch next.
Signal Types
Clinical Development
Trial design, endpoints, timelines, and regulatory strategy
Intellectual Property
Patent landscapes, filing strategies, and expiration risks
Scientific Validation
Publications, mechanism consistency, and platform claims
Hiring & Activity Signals
Hiring patterns, regulatory activity, and business development
Stay Informed
Subscribe for research and analysis on emerging biotechnology and pharmaceutical developments.
.